Is There a Generic for Farxiga?

The Short Answer on a Generic for Farxiga

Farxiga (dapagliflozin) is a widely prescribed SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. With a retail price often around $550 to $620 per month, many patients are asking: is there a generic for Farxiga? As of early 2026, there is no FDA-approved, marketed generic version of dapagliflozin available in the United States. AstraZeneca, the manufacturer, holds patent protections that have so far kept generic competitors off the US market. Because this situation can change, it is worth verifying the current status yourself — we explain how below.

That does not mean you are out of options. While waiting for a generic, several legitimate strategies can meaningfully reduce what you pay for Farxiga. This guide covers the current patent landscape, how to check for a generic, the safety context that makes switching a clinical decision, and every available savings route in the meantime.

How to Verify the Generic Status Yourself

Drug approvals move faster than any single article can, so the most reliable answer is the one you confirm at the source. The authoritative US register for small-molecule drugs like dapagliflozin is the FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), searchable free at fda.gov. If an approved generic dapagliflozin has been listed and marketed, it will appear there as an ANDA product with an “AB” therapeutic-equivalence rating to Farxiga. As of this writing, a search of the Orange Book shows only AstraZeneca’s own Farxiga 5 mg and 10 mg tablets — no marketed generic.

(A related FDA database, the Purple Book, lists biologics and their biosimilars. Dapagliflozin is a conventional small-molecule tablet, not a biologic, so the Orange Book — not the Purple Book — is the register that governs a dapagliflozin generic. Knowing which book to check helps you avoid confusion when you see references to both.)

Your pharmacist is another quick, current source: if a substitutable generic becomes available, they will know, because it changes what they can dispense. Reputable pharmacy and health-news outlets also track major generic launches. Treat any single “generic is coming in [year]” claim — including in older articles — with caution, because settlement terms and litigation can move the date.

Why There Is No Generic Yet

Farxiga received FDA approval in January 2014 for type 2 diabetes. It later gained additional approvals for heart failure (2020) and chronic kidney disease (2021), broadening its patient base substantially. AstraZeneca holds multiple patents covering dapagliflozin’s compound, formulation, and methods of use.

The primary composition-of-matter patent for dapagliflozin was extended beyond its original term, and additional Orange Book–listed patents extend protection further. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) challenging some of these patents under the Hatch-Waxman framework, and there have been reports of tentative FDA approvals — but a tentative approval is not the same as a marketed product, and settlements between AstraZeneca and generic makers commonly set specific future launch dates that are not always public.

Patent challenges and settlements in the pharmaceutical industry are complex and can change timelines unpredictably. Various sources have cited different windows for a US generic, and some have pointed to dates as early as the mid-2020s, but the exact timing remains uncertain — which is exactly why the Orange Book and your pharmacist are better guides than any predicted date. The bottom line for now: no generic dapagliflozin is marketed in the US as of early 2026.

How Farxiga Works — and Its Safety Context

Understanding why so many patients take Farxiga helps explain the urgency around the generic question. Farxiga belongs to the SGLT2 inhibitor class, which, per MedlinePlus, works by helping the kidneys remove glucose and excess fluid through the urine, lowering blood sugar.

Beyond glucose control, SGLT2 inhibitors have shown meaningful cardiovascular and kidney benefits. The DAPA-HF trial reported a reduced risk of cardiovascular death and heart-failure hospitalization, and the DAPA-CKD trial reported a reduced risk of kidney-function decline, kidney failure, or death from renal or cardiovascular causes. These findings led to expanded FDA indications and inclusion in guidelines from bodies such as the American Diabetes Association, the American Heart Association, and KDIGO — so a large patient population now depends on Farxiga and is directly affected by its cost.

Cost is not the only consideration, though. SGLT2 inhibitors carry specific safety points that MedlinePlus highlights: a risk of diabetic ketoacidosis (which can occur even with near-normal blood sugar — seek care for nausea, vomiting, abdominal pain, unusual tiredness, or trouble breathing), genital yeast infections and urinary tract infections, and dehydration. Patients are also often advised to pause the drug around surgery or serious illness. None of this is a reason to stop on your own — it is a reason that starting, stopping, or switching Farxiga is a decision to make with your prescriber, who can weigh the benefits against these risks for your situation.

Current Farxiga Pricing

Without insurance or a discount program, the retail price for Farxiga 10 mg (30 tablets) commonly ranges from about $550 to $620 at major US pharmacies, though prices vary by pharmacy and location and change over time. Approximate examples patients have reported include roughly $600–$615 at large chain pharmacies, somewhat less at warehouse-club pharmacies, and $470–$540 with a discount coupon depending on the pharmacy. Treat all of these as estimates and check current cash prices where you fill.

For patients taking Farxiga long-term, annual costs without assistance can exceed $6,000, which is why the savings routes below matter.

How to Save on Farxiga Right Now

While the answer to “is there a generic for Farxiga” remains no, these strategies can meaningfully reduce your cost.

AstraZeneca Savings Card

AstraZeneca offers a copay savings card for commercially insured patients that can lower the monthly cost substantially (for some patients to as little as $0), up to a maximum annual benefit. The card is available at farxiga.com and is not valid for patients with government insurance (Medicare, Medicaid, TRICARE, VA) due to federal anti-kickback rules. Check the official site for current terms and enrollment details.

AZ&Me Patient Assistance Program

For uninsured patients — or insured patients who still cannot afford Farxiga — AstraZeneca’s AZ&Me program may provide the medication at no cost to those who qualify. Eligibility is based on US residency, insurance status, and household income relative to the Federal Poverty Level; the exact income thresholds are set by the program and updated periodically, so confirm current limits and apply at azandmeapp.com. (Income thresholds and the Federal Poverty Level change each year — do not rely on a figure quoted in an older article.)

Prescription Discount Cards

GoodRx, RxSaver, and SingleCare offer coupons that can reduce Farxiga’s cash price, often modestly (roughly 10% to 20%). The savings are smaller than a generic would eventually deliver, but every dollar counts when you are paying out of pocket, and you can compare coupon prices across pharmacies before you fill.

Medicare Part D Strategies

Medicare beneficiaries should confirm Farxiga is on their Part D plan’s formulary and placed on an affordable tier. If it sits on a non-preferred tier, your prescriber can request a formulary exception. The Extra Help (Low-Income Subsidy) program can sharply reduce copays for those who qualify. The annual Part D out-of-pocket cap created by the Inflation Reduction Act (about $2,000, indexed and rising modestly each year) also limits total Part D spending — confirm the current-year figure, since it updates annually.

340B Pharmacies

340B-eligible pharmacies purchase drugs from manufacturers at steep, federally mandated discounts. If your healthcare provider participates in the 340B program, you may be able to access Farxiga at a reduced cost through their pharmacy.

Alternatives to Farxiga

If Farxiga’s cost is prohibitive and no program covers your situation, discuss alternatives with your doctor — never switch on your own.

Other SGLT2 inhibitors: Jardiance (empagliflozin) is the closest therapeutic alternative, with similar cardiovascular and renal benefits, but it is also brand-name with comparable pricing. As of early 2026, neither Jardiance nor Farxiga has a marketed US generic.

Older diabetes medications with generics: If you take Farxiga primarily for blood-sugar control, your doctor might consider adding or switching to a generic such as metformin, a sulfonylurea like glipizide, or pioglitazone — all far cheaper. These do not provide the same cardiovascular or kidney benefits as SGLT2 inhibitors, so the trade-off must be evaluated carefully with your clinician.

GLP-1 receptor agonists: Drugs like Ozempic and Trulicity offer cardiovascular benefits but are also brand-name and expensive. Generic timelines for various GLP-1s and SGLT2 inhibitors depend on their own patent situations.

Switching or stopping medication should never be done without medical guidance. If Farxiga was prescribed for heart failure or chronic kidney disease, the evidence supporting it in those conditions is strong, and alternatives may not offer equivalent outcomes.

What to Expect When a Generic Arrives

When a generic dapagliflozin eventually reaches the US market, patients can expect prices to fall over time. Based on typical brand-to-generic transitions, the first generic entrant often prices modestly below the brand, and prices tend to drop substantially as additional manufacturers enter over the following couple of years. Actual savings depend on how many manufacturers launch and how quickly.

To stay informed, periodically check the FDA’s Orange Book at fda.gov, which lists approved drug products and their generic status, and ask your pharmacist whether a substitutable generic is available. When one does launch, work with your pharmacist to switch appropriately.

Frequently Asked Questions

When will a Farxiga generic be available?

The exact date is uncertain and depends on the outcome of patent litigation and confidential settlement terms between AstraZeneca and generic manufacturers. Various sources have suggested different windows, and some tentative approvals have been reported, but no generic is marketed in the US as of early 2026. Rather than rely on a predicted year, check the FDA Orange Book and ask your pharmacist for the current status.

Is there a generic for Jardiance?

As of early 2026, no. Jardiance (empagliflozin) also lacks a marketed US generic, with a patent situation broadly similar to Farxiga’s. Confirm the current status in the Orange Book if you are researching alternatives.

Can I import Farxiga from another country?

Importing prescription drugs from other countries is generally prohibited under US federal law, though FDA enforcement for personal-use quantities has been limited. Prices abroad are often lower, but the legality and safety of importation remain gray areas, and product quality cannot be assured. Stick with FDA-approved sources whenever possible, and talk to your prescriber and pharmacist about legitimate savings options first.

Is the AstraZeneca savings card available to everyone?

No. The savings card is limited to patients with commercial (private) health insurance. Patients covered by Medicare, Medicaid, TRICARE, or VA benefits are ineligible due to federal anti-kickback regulations. Those patients should explore the AZ&Me patient assistance program or Medicare Extra Help.

Manage Your Costs Until a Generic Arrives

The accurate answer to “is there a generic for Farxiga” is: not yet in the United States, as of early 2026 — but that does not mean you have to pay full price. Between AstraZeneca’s savings card, the AZ&Me patient assistance program, discount cards, and Medicare subsidies, most patients can find a path to more affordable treatment. Verify the generic status yourself in the FDA Orange Book, keep any medication decisions with your prescriber, and when a generic does launch, work with your pharmacist to switch. For more ways to reduce prescription and healthcare costs, explore our healthcare costs guide.